loading page

A case of advanced biliary tract cancer with EGFR amplification that responded to Necitumumab and post-treatment resistance changes detected by liquid biopsy
  • +10
  • Makoto Sugimori,
  • Masaki Nishimura,
  • Kazuya Sugimori,
  • Sho Tsuyuki,
  • Akane Hirotani,
  • Haruo Miwa,
  • Takashi Kaneko,
  • Haruka Hirose,
  • Yoshiaki Inayama,
  • Akito Nozaki,
  • Kazushi Numata,
  • Chikara Kunisaki,
  • Shin Maeda
Makoto Sugimori
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Masaki Nishimura
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Kazuya Sugimori
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Sho Tsuyuki
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Akane Hirotani
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Haruo Miwa
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Takashi Kaneko
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Haruka Hirose
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Yoshiaki Inayama
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Akito Nozaki
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Kazushi Numata
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Chikara Kunisaki
Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center
Author Profile
Shin Maeda
Yokohama Shiritsu Daigaku Igakubu Daigakuin Igaku Kenkyuka Shokaki Naikagaku

Corresponding Author:[email protected]

Author Profile

Abstract

Background: Recent advances in cancer genome analysis and the practice of precision medicine have made it possible to identify fractions with rare genetic alterations. EGFR-amplified cancers are known to be rare fractions across organs and have a poor prognosis. The use of anti-EGFR antibody for EGFR-amplified cancers has been promising, but the evidence is not yet clear. Case: In this report, we describe the case of a 48-year-old man diagnosed with advanced gallbladder cancer. The patient was administered Gemcitabine plus Cisplatin, followed by S-1 monotherapy; however, disease progression was observed after two cycles of each regimen. Comprehensive genomic profiling test revealed EGFR-amplification, and the patient was treated with combination therapy with the anti-EGFR antibody Necitumumab, Gemcitabine, and Cisplatin. After two cycles of treatment, showed a reduction in tumor size, and the treatment response was evaluated as partial response. On day 90, after five cycles of treatment, tumor progression was confirmed. In addition, after disease progression, liquid biopsy revealed acquired pathogenic gene alterations suggesting anti-EGFR antibody resistance. Conclusions: This report supports the clinical benefit of anti-EGFR antibody for EGFR-amplified biliary tract cancers and the importance of genomic analysis in personalized therapy and drug resistance research.
Submitted to Cancer Reports
15 Feb 2024Review(s) Completed, Editorial Evaluation Pending
15 Feb 2024Submission Checks Completed
15 Feb 2024Assigned to Editor
20 Aug 2024Editorial Decision: Revise Major
09 Sep 20241st Revision Received
10 Sep 2024Submission Checks Completed
10 Sep 2024Assigned to Editor
10 Sep 2024Review(s) Completed, Editorial Evaluation Pending
11 Sep 2024Reviewer(s) Assigned
24 Oct 2024Editorial Decision: Accept